文献

J-GLOBAL ID：201002215573920405   整理番号：10A0337182

中あるいは低リスクの成人急性骨髄性白血病に対する寛解後治療としての同種幹細胞移植と化学療法: JALSG AML97試験の結果

Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study

著者 (14件)： SAKAMAKI Hisashi (Tokyo Metropolitan Komagome Hospital, Tokyo, JPN) ,  MIYAWAKI Shuichi (Tokyo Metropolitan Ohtsuka Hospital, Tokyo, JPN) ,  OHTAKE Shigeki (Kanazawa Univ. Graduate School of Medical Sci., Kanazawa, JPN) ,  EMI Nobuhiko (Fujita Health Univ., Aichi, JPN) ,  YAGASAKI Fumiharu (Saitama Medical School, Saitama, JPN) ,  MITANI Kinuko (Dokkyo Univ. School of Medicine, Tochigi, JPN) ,  MATSUDA Shin (Ohtanisinouchi Hospital, Kohriyama, JPN) ,  KISHIMOTO Yuji (Kansai Medical Univ., Osaka, JPN) ,  MIYAZAKI Yasushi (Nagasaki Univ. School of Medicine, Nagasaki, JPN) ,  ASOU Norio (Kumamoto Univ. School of Medicine, Kumamoto, JPN) ,  TAKAHASHI Masatomo (St. Marianna Univ. School of Medicine, Kawasaki, JPN) ,  OGAWA Yoshiaki (Tokai Univ. School of Medicine, Kanagawa, JPN) ,  HONDA Sumihisa (Nagasaki Univ. School of Medicine, Nagasaki, JPN) ,  OHNO Ryuzo (Aichi Cancer Center, Aichi, JPN)
資料名： International Journal of Hematology  (International Journal of Hematology)
巻： 91  号： 2  ページ： 284-292  発行年： 2010年03月 
JST資料番号： F0888A  ISSN： 0925-5710  CODEN： IJHEEY  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： ドイツ (DEU)  言語： 英語 (EN)

抄録/ポイント： 中あるいは低リスクの急性骨髄性白血病(AML)の成人患者の多...

シソーラス用語： *急性骨髄性白血病 ,...
準シソーラス用語： 寛解後治療 ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=10A0337182&from=J-GLOBAL&jstjournalNo=F0888A") }}

分類 (2件)： 腫ようの治療一般  (GE03031L) ,  血液の腫よう  (GK04000M)

引用文献 (24件)：

• OHNO, R. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. Cancer. 1993, 71, 12, 3888-3895
• KOBAYASHI, T. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol. 1996, 14, 1, 204-213
• MIYAWAKI, S. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia : the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol. 1999, 70, 2, 97-104
• BUCHNER, T. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML) : a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003, 21, 24, 4496-4504
• MOORE, JO. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age : Cancer and Leukemia Group B Study 9222. Blood. 2005, 105, 9, 3420-3427

タイトルに関連する用語 (9件)： リスク ,  成人 ,  急性骨髄性白血病 ,  寛解 ,  治療 ,  同種幹細胞移植 ,  化学療法 ,  JALSG ,  試験